Package Leaflet: Information for the User
Aciclovir Aurovitas, 200 mg, Tablets
Aciclovirum
Read the package leaflet carefully before taking the medicine, as it contains important information for the patient.
- Keep this package leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If you experience any side effects, including those not listed in this package leaflet, please inform your doctor or pharmacist. See section 4.
Contents of the Package Leaflet
- 1. What is Aciclovir Aurovitas and what is it used for
- 2. Important information before taking Aciclovir Aurovitas
- 3. How to take Aciclovir Aurovitas
- 4. Possible side effects
- 5. How to store Aciclovir Aurovitas
- 6. Contents of the pack and other information
1. What is Aciclovir Aurovitas and what is it used for
The active substance of Aciclovir Aurovitas is aciclovir. It belongs to a group of medicines called antivirals. It works by stopping the viruses that cause infections from multiplying in the body.
Indications for use of Aciclovir Aurovitas are:
- treatment of infections caused by the herpes simplex virus and herpes zoster;
- treatment of cold sores, genital herpes, and other infections caused by the herpes simplex virus;
- prevention of recurrence of herpes simplex;
- prevention of infections caused by the herpes simplex virus in people with weakened immunity, which means their body's defense system is not working properly.
2. Important information before taking Aciclovir Aurovitas
When not to take Aciclovir Aurovitas
- If you are allergic to aciclovir, valaciclovir, or any of the other ingredients of this medicine (listed in section 6).
- Do not take Aciclovir Aurovitas if any of the above applies to you. If you are not sure, consult your doctor or pharmacist before taking Aciclovir Aurovitas.
Warnings and precautions
Before taking Aciclovir Aurovitas, discuss with your doctor or pharmacist if:
- you have kidney problems;
- you are over 65 years old.
If you are unsure whether any of the above applies to you, consult your doctor or pharmacist before taking Aciclovir Aurovitas. It is very important to drink plenty of water while taking Aciclovir Aurovitas.
Aciclovir Aurovitas and other medicines
Tell your doctor or pharmacist about all the medicines you are taking, or have recently taken, including those obtained without a prescription, including herbal medicines.
- probenecid used to treat gout;
- cimetidine used to treat stomach ulcers;
- mycophenolate mofetil, used to prevent rejection of transplanted organs.
Pregnancy, breastfeeding, and fertility
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Some side effects, such as feeling drowsy or sleepy, may affect your ability to concentrate and react. Before driving or operating machinery, make sure that Aciclovir Aurovitas does not affect you in this way.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, which means it is essentially sodium-free.
3. How to take Aciclovir Aurovitas
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
How to take the medicine:
- Take the medicine by mouth.
- Swallow the tablet whole with a small amount of water.
- Start taking Aciclovir Aurovitas as soon as possible.
The dose of Aciclovir Aurovitas will depend on what it is prescribed for. Your doctor will discuss taking the medicine with you. If necessary, 800 mg tablets are also available.
Treatment of chickenpox and shingles
- The usual dose is one 800 mg tablet taken five times a day.
- Keep a 4-hour interval between doses.
- Suggested intake times are: 7:00, 11:00, 15:00, 19:00, and 23:00.
- Take Aciclovir Aurovitas for seven days.
Treatment of cold sores and genital herpes
- The usual dose is one 200 mg tablet taken five times a day.
- Keep a 4-hour interval between doses.
- Suggested intake times are: 7:00, 11:00, 15:00, 19:00, and 23:00.
- Take Aciclovir Aurovitas for five days or longer if your doctor advises.
Prevention of recurrence of herpes simplex
- The usual dose is one 200 mg tablet taken four times a day.
- Keep a 6-hour interval between doses.
- Take Aciclovir Aurovitas for as long as your doctor advises.
Prevention of infections caused by the herpes simplex virus in people with weakened immunity, which means their body's defense system is not working properly
- The usual dose is one 200 mg tablet taken four times a day.
- Keep a 6-hour interval between doses.
- Take Aciclovir Aurovitas for as long as your doctor advises.
Your doctor may adjust the dose of Aciclovir Aurovitas if:
- it is for a child;
- you are over 65 years old;
- you have kidney problems. If you have kidney problems, it is important to drink plenty of fluids while taking Aciclovir Aurovitas.
If any of the above applies to you, consult your doctor before taking Aciclovir Aurovitas.
Taking more than the recommended dose of Aciclovir Aurovitas
Aciclovir Aurovitas is not usually harmful, unless you take it in large amounts for several days. If you take too much Aciclovir Aurovitas, contact your doctor or pharmacist. Take the package leaflet with you.
Missing a dose of Aciclovir Aurovitas
- Take the missed dose as soon as possible. However, if it is almost time for the next dose, do not take the missed dose.
- Do not take a double dose to make up for a missed dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, Aciclovir Aurovitas can cause side effects, although not everybody gets them.
Allergic reactions(may affect up to 1 in 1000 people)
If you experience an allergic reaction, stop taking Aciclovir Aurovitas and contact your doctor immediately.
- rash, itching, or hives on the skin;
- swelling of the face, lips, tongue, or other parts of the body;
- difficulty breathing, wheezing, or breathing problems;
- fainting (syncope).
Other side effects:
Common(may affect up to 1 in 10 people):
- pains;
- dizziness;
- nausea or vomiting;
- diarrhea;
- abdominal pains;
- itching;
- rash;
- skin reaction caused by sunlight (photosensitivity);
- itching;
- fatigue;
- fever of unknown origin and feeling of fainting, especially when standing up.
Uncommon(may affect up to 1 in 100 people):
- itchy rash that looks like hives;
- hair loss.
Rare(may affect up to 1 in 1000 people):
- affecting some blood and urine test results;
- increased liver enzyme activity in the blood.
Very rare(may affect up to 1 in 10,000 people):
- reduced red blood cell count (anemia);
- reduced white blood cell count (leukopenia);
- reduced platelet count (thrombocytopenia);
- feeling weak;
- agitation or confusion;
- tremors or unsteady movements;
- hallucinations;
- seizures;
- feeling drowsy or sleepy;
- unsteady gait and lack of coordination;
- speech difficulties;
- inability to think logically or assess the situation;
- loss of consciousness (coma);
- paralysis of part or all of the body;
- behavioral, speech, and eye movement disorders;
- stiff neck and sensitivity to light;
- hepatitis;
- yellowing of the skin and whites of the eyes (jaundice);
- kidney problems - passing small amounts of urine or not passing urine;
- back pain, back pain in the kidney area, or just above the hip (kidney pain).
Reporting side effects
If you experience any side effects, including those not listed in this package leaflet, please inform your doctor or pharmacist.
Side effects can be reported directly to the Department of Drug Monitoring, Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Al. Jerozolimskie 181C, 02-222 Warszawa, tel.: (22) 49 21 301, fax: (22) 49 21 309, e-mail: ndl@urpl.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
5. How to store Aciclovir Aurovitas
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and carton after "EXP". The expiry date refers to the last day of that month.
There are no special storage instructions for this medicine.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
6. Contents of the pack and other information
What Aciclovir Aurovitas contains
The active substance is aciclovir. Each tablet contains 200 mg of aciclovir.
The other ingredients are: microcrystalline cellulose (type 101), sodium carboxymethylcellulose (type A), povidone K 30, colloidal anhydrous silica, magnesium stearate.
What Aciclovir Aurovitas looks like and contents of the pack
Tablet.
White or almost white, round, biconvex, uncoated tablets with "AR 200" engraved on one side and smooth on the other.
Aciclovir Aurovitas tablets are packaged in PVC/Aluminum blisters, in a cardboard box.
Pack sizes: 20, 25, 30, 35, 50, 70, 100, and 500 tablets.
Not all pack sizes may be marketed.
Marketing authorization holder
Aurovitas Pharma Polska Sp. z o.o.
ul. Sokratesa 13D lokal 27
01-909 Warszawa
Manufacturer/Importer
APL Swift Services (Malta) Ltd
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
Generis Farmacêutica, S.A.
Rua João de Deus, n.º 19, Venda Nova
2700-487 Amadora
Portugal
Arrow Generiques – Lyon
26 avenue Tony Garnier
69007 Lyon
France
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Belgium:
Aciclovir AB 200 mg tablets
Czech Republic:
Aciclovir Aurovitas
France:
Aciclovir Arrow génériques 200 mg tablet
Germany:
Aciclovir PUREN 200 mg tablets
Netherlands:
Aciclovir Aurobindo 200 mg, tablets
Poland:
Aciclovir Aurovitas
Portugal:
Aciclovir Generis Phar
Romania:
Aciclovir Aurobindo 200mg tablets
Spain:
Aciclovir Aurobindo 200 mg comprimidos EFG
Date of last revision of the package leaflet: